CARDIOFLOW-B released its interim results, with a loss attributable to shareholders of RMB 2.163 million, a year-on-year decrease of 96.17%
CARDIOFLOW-B released its interim results for the period ending June 30, 2025, with revenue of 229 million yuan, an increase of 2.67% year-on-year. The loss attributable to shareholders was 2.163 million yuan, a decrease of 96.17% year-on-year, with a basic loss per share of 0.09 yuan. The revenue growth was mainly driven by the global commercialization of the VitaFlow Liberty® transcatheter aortic valve and its retrievable delivery system, as well as the steady progress of the AnchorMan® left atrial appendage occlusion system and guiding system in both domestic and international markets
According to the Zhitong Finance APP, CARDIOFLOW-B (02160) released its interim results for the six months ending June 30, 2025, reporting revenue of 229 million yuan, an increase of 2.67% year-on-year; the loss attributable to equity shareholders of the company was 2.163 million yuan, a decrease of 96.17% year-on-year; basic loss per share was 0.09 cents.
The announcement stated that the increase in revenue was mainly due to the continued advancement of the group's VitaFlow Liberty® transcatheter aortic valve and retrievable delivery system in global commercialization, which significantly boosted overseas revenue; and the steady progress of the group's AnchorMan® left atrial appendage occlusion system and AnchorMan® left atrial appendage guiding system in commercialization in China and overseas
